Actualités en anatomie et cytologie pathologiques dans le cancer du sein

Abstract

AbstractBreast cancer (BC) is highly heterogeneous in clinical, morphological and biological terms. Even if certain tumors present the same phenotype, their biological characteristics and response to treatment may differ. High-throughput molecular analyses have enabled us to better understand the biology of these cancers and identify molecular subclasses. Morphological classification of SCs remains paramount in constant evolution, and we will cite some changes in the new 2019 WHO classification (5th edition) including new entities and updates to the diagnostic criteria for certain tumor types. We will also see the introduction of biological parameters in patient stratification, biomarkers that are known but are experiencing renewed interest such as HER2 and newly introduced in breast pathology such as PD-L1, which are of interest for their impact on therapeutic decision. We will conclude with a brief overview of emerging technologies, including artificial intelligence, which could prove invaluable in routine breast cancer assessment or the prediction of the recurrence risk in the near future. All these advances contribute to personalized care for patients with BC.